Form 8-K - Current report:
SEC Accession No. 0000950170-24-133668
Filing Date
2024-12-05
Accepted
2024-12-05 16:05:09
Documents
11
Period of Report
2024-12-04
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K hlvx-20241204.htm   iXBRL 8-K 43017
  Complete submission text file 0000950170-24-133668.txt   158122

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT hlvx-20241204.xsd EX-101.SCH 24829
13 EXTRACTED XBRL INSTANCE DOCUMENT hlvx-20241204_htm.xml XML 4691
Mailing Address 321 HARRISON AVE, SUITE 500 BOSTON MA 02118
Business Address 321 HARRISON AVE, SUITE 500 BOSTON MA 02118 (617) 213-5054
HilleVax, Inc. (Filer) CIK: 0001888012 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41365 | Film No.: 241529100
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)